Moreover, it has been reported that the dual PI3K/mTOR inhibitor BEZ235 enhances antitumor activities by promoting autophagy in ESCC cells through the inhibition of the PI3K/Akt/mTOR signaling pathway 146. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.